Literature DB >> 31709547

Prospects for the involvement of cancer stem cells in the pathogenesis of osteosarcoma.

Sama Izadpanah1, Parastoo Shabani1, Ali Aghebati-Maleki1,2, Amir Baghbanzadeh1, Ali Fotouhi3, Amir Bisadi3, Leili Aghebati-Maleki1,4, Behzad Baradaran1.   

Abstract

Osteosarcoma (OS) is one of the most common bone tumors in children and adolescents that cause a high rate of mortality in this age group and tends to be metastatic, in spite of chemotherapy and surgery. The main reason for this can be returned to a small group of malignant cells called cancer stem cells (CSCs). OS-CSCs play a key role in the resistance to treatment and relapse and metastasis through self-renewal and differentiation abilities. In this review, we intend to go through the different aspects of this malignant disease, including the cancer stem cell-phenotype, methods for isolating CSCs, signaling pathways, and molecular markers in this disease, and drugs showing resistance in treatment efforts of OS.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer stem cell; drug resistance; osteosarcoma; treatment

Mesh:

Substances:

Year:  2019        PMID: 31709547     DOI: 10.1002/jcp.29344

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  10 in total

1.  Scaffold-based 3D cellular models mimicking the heterogeneity of osteosarcoma stem cell niche.

Authors:  Giada Bassi; Silvia Panseri; Samuele Maria Dozio; Monica Sandri; Elisabetta Campodoni; Massimiliano Dapporto; Simone Sprio; Anna Tampieri; Monica Montesi
Journal:  Sci Rep       Date:  2020-12-18       Impact factor: 4.379

Review 2.  Advanced Multi-Dimensional Cellular Models as Emerging Reality to Reproduce In Vitro the Human Body Complexity.

Authors:  Giada Bassi; Maria Aurora Grimaudo; Silvia Panseri; Monica Montesi
Journal:  Int J Mol Sci       Date:  2021-01-26       Impact factor: 5.923

Review 3.  Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma.

Authors:  Vafa Meftahpour; Ali Aghebati-Maleki; Ali Fotouhi; Elham Safarzadeh; Leili Aghebati-Maleki
Journal:  EXCLI J       Date:  2022-01-12       Impact factor: 4.068

Review 4.  The Roles of Noncoding RNAs in the Development of Osteosarcoma Stem Cells and Potential Therapeutic Targets.

Authors:  Jinxin Liu; Guanning Shang
Journal:  Front Cell Dev Biol       Date:  2022-02-16

5.  Construction of an Immune-Related lncRNA Signature That Predicts Prognosis and Immune Microenvironment in Osteosarcoma Patients.

Authors:  Yi He; Haiting Zhou; Haoran Xu; Hongbo You; Hao Cheng
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

Review 6.  Chemoresistance-Related Stem Cell Signaling in Osteosarcoma and Its Plausible Contribution to Poor Therapeutic Response: A Discussion That Still Matters.

Authors:  Sara R Martins-Neves; Gabriela Sampaio-Ribeiro; Célia M F Gomes
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

7.  Trophinin Is an Important Biomarker and Prognostic Factor in Osteosarcoma: Data Mining from Oncomine and the Cancer Genome Atlas Databases.

Authors:  Pan Cai; Yan Lu; Zhifeng Yin; Xiuhui Wang; Xiaoxiao Zhou; Zhuokai Li
Journal:  Biomed Res Int       Date:  2021-07-06       Impact factor: 3.411

8.  Nanoparticle enhanced combination therapy for stem-like progenitors defined by single-cell transcriptomics in chemotherapy-resistant osteosarcoma.

Authors:  Li Wang; Xiaojia Huang; Xinru You; Tianqi Yi; Bing Lu; Jiali Liu; Guohao Lu; Minglin Ma; Changye Zou; Jun Wu; Wei Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-09-25

Review 9.  Functional interplay between long non-coding RNAs and the Wnt signaling cascade in osteosarcoma.

Authors:  Jieyu He; Lin Ling; Zhongyue Liu; Xiaolei Ren; Lu Wan; Chao Tu; Zhihong Li
Journal:  Cancer Cell Int       Date:  2021-06-15       Impact factor: 5.722

10.  Cytoskeletal Actin Structure in Osteosarcoma Cells Determines Metastatic Phenotype via Regulating Cell Stiffness, Migration, and Transmigration.

Authors:  Kouji Kita; Kunihiro Asanuma; Takayuki Okamoto; Eiji Kawamoto; Koichi Nakamura; Tomohito Hagi; Tomoki Nakamura; Motomu Shimaoka; Akihiro Sudo
Journal:  Curr Issues Mol Biol       Date:  2021-09-24       Impact factor: 2.976

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.